EDIT News and Press, Editas Medicine Inc. From 12/28/23

2023-12-28 13:10:55 ET Summary Editas Medicine is transitioning from platform development to establishing itself as a key player in the commercial therapeutics market. The company's strategic priorities include fast-tracking the clinical development of EDIT-301, shifting focus to ...

2023-12-25 23:44:10 ET Summary Editas Therapeutics is developing a gene-editing therapy called reni-cel for Sickle Cell Disease and beta-thalassemia. The competitive landscape for gene-editing therapies for SCD is strengthening with three leading contenders: Casgevy by Vertex Phar...

2023-12-23 08:02:00 ET It's fair to say that Editas Medicine (NASDAQ: EDIT) is an ailing biotech. Over the past three years, its share price has fallen by 83% as it abandoned parts of its pipeline and laid off staff. Despite its supposedly powerful gene-editing technology, the compa...

2023-12-13 09:33:01 ET More on Editas, Vertex, etc. Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript) Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed Editas Medicine, Inc. (EDIT)...

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 f or CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clini...

2023-12-11 17:50:27 ET Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update December 11, 2023 1:00 PM ET Company Participants Cristi Barnett - Corporate Communications & IR Gilmore O'Neill - CEO Baisong Mei - CMO Caren...

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40% All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301 infusion EDIT-301 was well-tolerated and demonstrated a safety p...

2023-12-05 07:00:00 ET Biotechs specializing in gene editing are making serious strides, but many are still clinical-stage companies. Their lack of consistent revenue and profits has been a turn-off for investors in recent years, which is why many of them have substantially lagged the marke...

2023-12-04 05:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-29 14:28:48 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the hottest opportunities can be found in biotech stocks . Look at gene editing companies, like CRISPR Therapeutics (NASDAQ: CRSP ), for example. Since the start of...